Richard J Kelly - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Richard J Kelly

Showing results (21-30 of 40) with videos related to

Pageof 4

Sort By:

Annals of Hematology|April 29, 2025

What are the most important quality of life domains for patients with aplastic anemia and paroxysmal nocturnal hemoglobinuria?Katherine J Taylor, Susanne Singer, Saskia Langemeijer, et al.

Blood|April 5, 2011

Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survivalRichard J Kelly, Anita Hill, Louise M Arnold, et al.

British Journal of Cancer|April 10, 2026

Apoptotic modulators enhance oncolytic virus-induced cytokine killing in acute myeloid leukaemia (AML)Basem Askar, Samuel Heaton, Tyler Barr, et al.

Orphanet Journal of Rare Diseases|October 13, 2024

A machine learning algorithm for the detection of paroxysmal nocturnal haemoglobinuria (PNH) in UK primary care electronic health recordsAmanda Worker, Hadley Mahon, Jack Sams, et al.

Journal of Comparative Effectiveness Research|July 7, 2022

The cost-effectiveness, of pegcetacoplan compared with ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria, in a UK settingZalmai Hakimi, Koo Wilson, Eoin McAughey, et al.

Ejhaem|July 25, 2025

Safety, Efficacy, and Patient-Reported Outcomes From a Phase 2 Randomized Trial of Pozelimab and Cemdisiran Combination in Patients With Paroxysmal Nocturnal HemoglobinuriaJun-Ho Jang, Raymond Siu Ming Wong, Christopher Hartford, et al.

Cancer|February 13, 2025

Maintenance therapy with the FMS-like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS-like tyrosine kinase 3-internal tandem duplication acute myeloid leukemia: A phase 2 studyEmmanuel Gyan, Mark D Minden, Kohmei Kubo, et al.

Advances in Therapy|April 4, 2024

Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension StudyChristopher J Patriquin, Andrija Bogdanovic, Morag Griffin, et al.

British Journal of Haematology|February 19, 2025

Oral iptacopan for paroxysmal nocturnal haemoglobinuria-First real-world experienceRichard J Kelly, Austin G Kulasekararaj, Louise M Arnold, et al.

Advances in Therapy|July 28, 2025

Efficacy and Safety Maintained up to 3 Years in Adults with Paroxysmal Nocturnal Hemoglobinuria Receiving PegcetacoplanCarlos de Castro, Richard J Kelly, Morag Griffin, et al.

Pageof 4

Search research articles

Showing results (21-30 of 40) with videos related to

Sort By:

Pageof 4

Annals of Hematology|April 29, 2025

What are the most important quality of life domains for patients with aplastic anemia and paroxysmal nocturnal hemoglobinuria?Katherine J Taylor, Susanne Singer, Saskia Langemeijer, et al.

Blood|April 5, 2011

Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survivalRichard J Kelly, Anita Hill, Louise M Arnold, et al.

British Journal of Cancer|April 10, 2026

Apoptotic modulators enhance oncolytic virus-induced cytokine killing in acute myeloid leukaemia (AML)Basem Askar, Samuel Heaton, Tyler Barr, et al.

Orphanet Journal of Rare Diseases|October 13, 2024

A machine learning algorithm for the detection of paroxysmal nocturnal haemoglobinuria (PNH) in UK primary care electronic health recordsAmanda Worker, Hadley Mahon, Jack Sams, et al.

Journal of Comparative Effectiveness Research|July 7, 2022

The cost-effectiveness, of pegcetacoplan compared with ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria, in a UK settingZalmai Hakimi, Koo Wilson, Eoin McAughey, et al.

Ejhaem|July 25, 2025

Cancer|February 13, 2025

Advances in Therapy|April 4, 2024

British Journal of Haematology|February 19, 2025

Oral iptacopan for paroxysmal nocturnal haemoglobinuria-First real-world experienceRichard J Kelly, Austin G Kulasekararaj, Louise M Arnold, et al.

Advances in Therapy|July 28, 2025

Efficacy and Safety Maintained up to 3 Years in Adults with Paroxysmal Nocturnal Hemoglobinuria Receiving PegcetacoplanCarlos de Castro, Richard J Kelly, Morag Griffin, et al.

Pageof 4